REVERSED INNOVATION
We find new indications
for existing technologies
THE MEANING OF
REVERSED INNOVATION
We find new indications for existing technologies.
Through our research, we work relentlessly to improve lives by addressing unmet medical needs.
Reversed Innovation is our core value.
As a leader in the biopharmaceutical industry, reversed innovation aligns with the broader theme, as we take an existing product or technology and use it to address a new or previously overlooked or unconsidered medical problem or condition.
TRUSTED DEVELOPMENT
Dr. Claus J. Møller-San Pedro is the company CEO.
Dr. Møller co-founded and secured successful IPOs of 3 companies in the BioPharma Industry: OXiGENE Inc. (OTLC); Genmab A/S (GMAB) and Y-mAbs Therapeutics, Inc. (YMAB).
Our latest investor presentation is always available here together with annual reports, financial information and other news from AFYX.
NEWS
Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients
Vienna, Austria – May 5, 2025 Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment Presented at ESTRO 2025. Clinical Study Demonstrates Improved Locoregional Control with Nimorazole in Advanced Head and Neck Cancer....
Lunatus and AFYX Therapeutics A/S Announce Distribution and Sales Collaboration
Hørsholm, Denmark – April 23, 2025 Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX's induction of labor product, Gefena (Misoprostol 25μg tablet). Under this agreement, Lunatus will distribute,...
Interim Financial Report Q4 2024
In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers in Norway—a trend we expect...
AFYX THERAPEUTICS HQ
Slotsmarken 11, 1.tv.
DK-2970 Hørsholm
Denmark
VAT: 38793594
Phone: +45 7174 7174
info@afyxtx.com
INPHENA NORWAY
Gaustadalléen 21
NO-0349 Oslo
Norway
VAT: 922 558 221
Phone: +47 2396 7174